Journey Medical Corp (DERM)

Punch & Associates Investment Management Inc. has acquired 536,000 shares of Journey Medical Corporation (NASDAQ:DERM) valued at approximately $3.8 million, representing a 1.95% stake. The company's shares are trading at $7.55, and it recently reported exceeding revenue expectations with $18.51 million in sales for the last quarter. Analyst sentiment is mixed, with an average "Hold" rating and a consensus price target of $14.00.

J. Goldman & Co LP has initiated a new position in Journey Medical Corporation (NASDAQ:DERM), purchasing 137,584 shares valued at approximately $974,000. This move contributes to a total institutional ownership of 7.25% in the company, with other investors like Wasatch Advisors LP and UBS Group AG also adjusting their stakes. Journey Medical recently surpassed analyst expectations for quarterly revenue and EPS, although the stock's overall analyst rating remains a "Hold" with a mixed price target consensus.

Journey Medical (DERM) saw its stock rise modestly after reporting Q2 revenue of US$18.5m and a significantly narrowed net loss of US$0.3m, largely driven by its Emrosi product which contributed US$8.1m. While the company is moving closer to profitability, concerns remain about its reliance on Emrosi, payer friction, and liquidity risk. Investors are watching to see if Emrosi can lead to sustained profitability without substantial additional spending.

Journey Medical (FBIO) reported a 23% year-over-year revenue increase to $18.5 million in Q2 2026, primarily driven by strong performance from its rosacea product, Emrosi, which generated $8.1 million in net revenue and saw a 20% sequential rise in prescriptions. The company achieved positive adjusted EBITDA of $2.9 million and narrowed its GAAP net loss significantly, projecting continued EBITDA positivity for the rest of 2026 due to expanding formulary coverage and sales momentum. Key risks involve overcoming prescription friction caused by prior authorizations and double-step therapy requirements for Emrosi, as well as potential quarterly fluctuations in secondary products like QBREXZA.

B. Riley Financial has reaffirmed its "Buy" rating for Journey Medical (NASDAQ:DERM), increasing its price target from $12 to $15, which suggests a 133.28% potential upside. Despite mixed analyst opinions, the company recently surpassed quarterly expectations, reporting an adjusted loss of $0.01 per share against an anticipated $0.02 loss, with revenues also slightly exceeding forecasts. Several institutional investors have adjusted their holdings in DERM, indicating growing interest.